ZEOX
Zeo ScientifiX, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines. The company's lead product candidate is Zofin, an acellular biologic therapeutic derived from perinatal sources, which is in Phase I/II clinical trial to treat COVID-19, chronic obstructive pulmonary disease, and knee osteoarthritis. It also provides Patient Pure X, an autologous blood-derived biologic technology, that helps the body's natural ability to decrease cellular inflammation and promote tissue healing. In addition, the company develops and distributes products that incorporate its proprietary ingredients for products to be used in topical aesthetic applications; ZEO GROW X, a professional-grade formula that delivers a concentrated dose of topical exosomes that help support follicular function; ZEO GROW BOOST; and EXO FOLLICLE FUEL. The company was formerly known as Organicell Regenerative Medicine, Inc. and changed its name to Zeo ScientifiX, Inc. in February 2024. Zeo ScientifiX, Inc. was incorporated in 2011 and is headquartered in Davie, Florida.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.12 | $1M | -$485,000 |
| 2025 Q4 | -0.12 | $2M | -$383,000 |
| 2025 Q3 | -0.32 | $1M | -$280,000 |
| 2025 Q2 | -0.22 | $1M | -$143,000 |
| 2025 Q1 | -0.20 | $1M | $65,000 |
| 2024 Q4 | -0.73 | $1M | $895,734 |
| 2024 Q3 | -0.16 | $1M | -$831,026 |
| 2021 Q3 | -0.00 | $1M | -$681,450 |